scholarly journals Telerehabilitation in Multiple Sclerosis: Results of a Randomized Feasibility and Efficacy Pilot Study

2018 ◽  
Vol 10 (2) ◽  
pp. 55-64 ◽  
Author(s):  
Cecilie Fjeldstad-Pardo ◽  
Amy Thiessen ◽  
Gabriel Pardo
Keyword(s):  
Multiple Sclerosis ◽  
Patient Reported Outcomes ◽  
Exercise Program ◽  
Comparable Efficacy ◽  
Home Based ◽  
Included Patient ◽  
Patient Reported ◽  
Group 2 ◽  
Objective Outcomes ◽  
Functional Gait

A prospective, randomized, three-arm, evaluator blinded study to demonstrate the feasibility of a telerehabilitation (TR) program in individuals with ambulatory deficits secondary to Multiple Sclerosis (MS) and evaluate its efficacy when compared to conventional on-site physical therapy (PT) was completed. Thirty participants were evaluated at baseline and randomized to one of three groups with intervention lasting 8 weeks: Group 1 (control)- customized unsupervised home-based exercise program (HEP) 5 days a week; Group 2 (TR)- remote PT supervised via audio/visual real-time telecommunication twice weekly; Group 3 (PT)- in-person PT at the medical facility twice weekly. Outcomes included patient reported outcomes (PROs) obtained through questionnaires, and measurements of gait and balance performed with bedside tests and a computerized system. Functional gait assessment improved from baseline in all three groups. There were no significant differences between the TR and the conventional PT groups for a variety of outcome measures. TR is a feasible method to perform PT in persons with MS and has comparable efficacy to conventional in-person PT as measured by patient reported outcomes and objective outcomes of gait and balance.

scholarly journals Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis

2021 ◽  
Author(s):  
Kristin Galetta ◽  
Chinmay Deshpande ◽  
Brian C. Healy ◽  
Bonnie Glanz ◽  
Marina Ziehn ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Patient Reported Outcomes ◽  
Patient Reported

The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis

2012 ◽  
Vol 21 (10) ◽  
pp. 1677-1684 ◽  
Author(s):  
Brian C. Healy ◽  
Irene R. Degano ◽  
Ana Schreck ◽  
David Rintell ◽  
Howard Weiner ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Patient Reported Outcomes ◽  
Patient Reported ◽  
The Impact

PATIENT-REPORTED OUTCOMES AND DISABILITY IN MULTIPLE SCLEROSIS

2015 ◽  
Vol 86 (11) ◽  
pp. e4.32-e4
Author(s):  
Neil Scolding ◽  
Hongwei Wang ◽  
Yan Liu ◽  
Lawrence Steinman
Keyword(s):  
Multiple Sclerosis ◽  
Patient Reported Outcomes ◽  
Short Form ◽  
Minimum Important Difference ◽  
Point Change ◽  
Clinical Difference ◽  
Sf 36 ◽  
Patient Reported ◽  
Edss Score ◽  
Multiple Sclerosis Patients

In the 2-year, phase 3 CARE-MS II study (NCT00548405), alemtuzumab demonstrated superior clinical and patient-reported outcomes (PROs) over subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis patients who had inadequate efficacy response to prior therapy. To further evaluate the relationship between PROs and disability, Short-Form 36-Item (SF-36) survey physical component summary (PCS) and mental component summary (MCS), and Functional Assessment of Multiple Sclerosis (FAMS) scores were analysed against Expanded Disability Status Scale (EDSS) outcomes, adjusted for baseline characteristics and randomisation arm. A 1.0-point difference in baseline EDSS score was associated with 2.0-point PCS, 0.8-point MCS, and 4.0-point FAMS worsening over 12 months (all P<0.001). A 1.0-point annualised EDSS score worsening corresponded to a 2.2-point PCS, 1.6-point MCS, and 6.0-point FAMS worsening (all P<0.001). For baseline EDSS score <4.0, 1.0-point annualised worsening was associated with 7.2-point FAMS and 2.0-point MCS worsening (both P<0.001). For baseline EDSS score ≥4.0, 1.0-point worsening corresponded to worsening on FAMS (2.4 points; P=0.04), but not MCS (P=0.82). Given that a half-point EDSS change is considered the minimum reliably measurable clinical difference, a 1.0-point change in SF-36 PCS and MCS or 3.0-point change in FAMS may represent a minimum important difference in PRO for multiple sclerosis patients.

scholarly journals Comparative Effectiveness Study of Home-Based Interventions to Prevent CA-MRSA Infection Recurrence

Antibiotics ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 1105
Author(s):  
Jonathan N. Tobin ◽  
Suzanne Hower ◽  
Brianna M. D’Orazio ◽  
María Pardos de la Gándara ◽  
Teresa H. Evering ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Patient Reported Outcomes ◽  
Health Workers ◽  
Home Visits ◽  
Self Report ◽  
Household Member ◽  
Surveillance Culture ◽  
Home Based ◽  
Patient Reported ◽  
Household Members

Recurrent skin and soft tissue infections (SSTI) caused by Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) or Methicillin-Sensitive Staphylococcus aureus (CA-MSSA) present treatment challenges. This community-based trial examined the effectiveness of an evidence-based intervention (CDC Guidelines, topical decolonization, surface decontamination) to reduce SSTI recurrence, mitigate household contamination/transmission, and improve patient-reported outcomes. Participants (n = 186) were individuals with confirmed MRSA(+)/MSSA(+) SSTIs and their household members. During home visits; Community Health Workers/Promotoras provided hygiene instructions; a five-day supply of nasal mupirocin; chlorhexidine for body cleansing; and household disinfecting wipes (Experimental; EXP) or Usual Care Control (UC CON) pamphlets. Primary outcome was six-month SSTI recurrence from electronic health records (EHR). Home visits (months 0; 3) and telephone assessments (months 0; 1; 6) collected self-report data. Index patients and participating household members provided surveillance culture swabs. Secondary outcomes included household surface contamination; household member colonization and transmission; quality of life; and satisfaction with care. There were no significant differences in SSTI recurrence between EXP and UC in the intent-to-treat cohort (n = 186) or the enrolled cohort (n = 119). EXP participants showed reduced but non-significant colonization rates. EXP and UC did not differ in household member transmission, contaminated surfaces, or patient-reported outcomes. This intervention did not reduce clinician-reported MRSA/MSSA SSTI recurrence. Taken together with other recent studies that employed more intensive decolonization protocols, it is possible that a promotora-delivered intervention instructing treatment for a longer or repetitive duration may be effective and should be examined by future studies.

scholarly journals Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosis

2018 ◽  
Vol 23 ◽  
pp. 33-39 ◽  
Author(s):  
Kathryn C. Fitzgerald ◽  
Diane Vizthum ◽  
Bobbie Henry-Barron ◽  
Amy Schweitzer ◽  
Sandra D. Cassard ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Calorie Restriction ◽  
Patient Reported Outcomes ◽  
Patient Reported

scholarly journals Home-based, square-stepping exercise program among older adults with multiple sclerosis: results of a feasibility randomized controlled study

2018 ◽  
Vol 73 ◽  
pp. 136-144 ◽  
Author(s):  
Emerson Sebastião ◽  
Edward McAuley ◽  
Ryosuke Shigematsu ◽  
Brynn C. Adamson ◽  
Rachel E. Bollaert ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Older Adults ◽  
Exercise Program ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Randomized Controlled ◽  
Home Based ◽  
Stepping Exercise
Sign in / Sign up

Export Citation Format

Share Document